Second Sight Medical Products Inc
NASDAQ:EYES
Intrinsic Value
Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of EYES.
Fundamental Analysis
Balance Sheet Decomposition
Second Sight Medical Products Inc
Second Sight Medical Products Inc
Earnings Waterfall
Second Sight Medical Products Inc
|
Revenue
|
0
USD
|
|
Cost of Revenue
|
130k
USD
|
|
Gross Profit
|
130k
USD
|
|
Operating Expenses
|
-9.1m
USD
|
|
Operating Income
|
-8.9m
USD
|
|
Other Expenses
|
12k
USD
|
|
Net Income
|
-8.9m
USD
|
Free Cash Flow Analysis
Second Sight Medical Products Inc
EYES Profitability Score
Profitability Due Diligence
Second Sight Medical Products Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Second Sight Medical Products Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
EYES Solvency Score
Solvency Due Diligence
Second Sight Medical Products Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Second Sight Medical Products Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EYES Price Targets Summary
Second Sight Medical Products Inc
Ownership
EYES Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
EYES Price
Second Sight Medical Products Inc
| Average Annual Return | -40.03% |
| Standard Deviation of Annual Returns | 28.42% |
| Max Drawdown | -93% |
| Market Capitalization | 163.2m USD |
| Shares Outstanding | 39 409 200 |
| Percentage of Shares Shorted | 3.85% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. The company is headquartered in Sylmar, California and currently employs 15 full-time employees. The company went IPO on 2014-11-19. The firm manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). The company is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.
You don't have any saved screeners yet
